RM-028 Gemcitabine in combination with capecitabine compared with gemcitabine combined with erlotinib in locally advanced or metastatic pancreatic cancer

Khatri, Priyanka; Kumari, Poonam; Beniwal, Surender; Samdariya, Saurabh

doi:10.1093/annonc/mdw201.27

Cited by 1 publication

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the included trials, gemcitabine was the common control group. Seven anticancer mechanisms were analyzed, including antiangiogenetic agents (bevacizumab, aflibercept, elpamotide, and vandetanib), multi-tyrosine kinase receptor inhibitors (axitinib, dasatinib, masitinib, sorafenib, and sunitinib), immune therapy (WT1 vaccine, and IMM-101), epidermal growth factor receptor (erlotinib, cetuximab, and nimotuzumab), taxanes (docetaxel, cationic liposomal paclitaxel, and nab-paclitaxel), platinum (oxaliplatin and cisplatin), fluoropyrimidine alone (S-1 and capecitabine), and fluoropyrimidine-based (FOLFIRINOX: folinic acid, fluorouracil, irinotecan, and oxaliplatin) (Figure S1) [5,6,7,15,16,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45].…”

Section: Resultsmentioning

confidence: 99%

“…The most bias without blinding was observed in about 48% of included trials with open-label designed [15,21,23,24,25,26,27,28,30,33,36,39,40,42,45]. About 40% of included trial didn’t provide the detail information of allocation method [5,15,20,21,22,29,30,33,34,35,37,41,44,45]. One trial with unclear risk was due to coming from the meeting abstracts [22].…”

Section: Resultsmentioning

confidence: 99%

“…About 40% of included trial didn’t provide the detail information of allocation method [5,15,20,21,22,29,30,33,34,35,37,41,44,45]. One trial with unclear risk was due to coming from the meeting abstracts [22].…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Network Meta-Analysis of Efficacy and Safety of Chemotherapy and Target Therapy in the First-Line Setting of Advanced Pancreatic Cancer

Lin

Yang

Lin

et al. 2019

Cancers

View full text Add to dashboard Cite

Both gemcitabine and fluoropyrimidine are recommended backbones in the first-line treatment of pancreatic ductal adenocarcinoma (PDAC). To compare the efficacy and safety of these two therapeutic backbones, and to investigate the optimal therapies, we conducted a network meta-analysis. By retrospective analysis of randomized controlled trials (RCT), the most preferred therapeutic regimen may be predicted. The eligible RCTs of the gemcitabine-based therapies and fluoropyrimidine-based therapies were searched up to 31 August 2019. In a frequentist network meta-analysis, treatments were compared and ranked according to overall survival (OS) and progression-free survival (PFS). Thirty-two trials with 10,729 patients were included. The network meta-analyses results for overall survival and progression-free survival showed that fluoropyrimidine-based therapy seems to be the most effective treatment choice. Compared to gemcitabine combined with taxanes or immunotherapy, fluoropyrimidine-based therapy had comparable treatment effects (PFS: 0.67, p-Value = 0.11; 0.76, p-Value = 0.32; OS: 0.80, p-Value = 0.16; 0.77, p-Value = 0.21). Moreover, the combination of immunotherapy and gemcitabine had tolerable toxicities. Based on current evidence, fluoropyrimidine-based therapies and the combination of gemcitabine and taxanes were the most effective therapies in the advanced pancreatic cancer, and the combination of immunotherapy and gemcitabine can be developed into a new form of therapy.

show abstract